Empress Therapeutics Uses AI for Drug Candidate Development
Biotechnology firm Empress Therapeutics is leveraging artificial intelligence and genetic data to accelerate the development of new drug candidates. The company aims to create treatments for a range of serious unmet medical needs.
Biotechnology company Empress Therapeutics is focused on developing novel drug candidates by employing artificial intelligence and genetic data. The company's proprietary platform aims to expedite the journey of these candidates into clinical trials.
The firm's Chemilogics™ platform utilizes evolutionary biology, human molecular and genetic data, along with AI analysis. This integration allows for the identification and refinement of endogenous, drug-like molecules, aiming to produce advanced small-molecule drug candidates.
Founded by Jason Park and Joseph Kelleher, Empress Therapeutics operates out of Cambridge, Massachusetts. While specific funding details are not publicly disclosed, the company shows metrics indicating growth and market interest. Its focus lies in creating treatments for significant and unaddressed diseases.
Empress Therapeutics seeks to reduce the cost and time associated with drug development. By combining AI with biological data, the company is developing a new approach for identifying and advancing therapeutic molecules.